Mengsi Cai

Wenzhou Key Laboratory Of Interdisciplinary And Translational Medicine, Wenzhou Key Laboratory Of Heart And Lung
Wenzhou, 325035, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

The landscape of MET alterations in non-small cell lung cancer in Southeastern China: a real-world study.

The landscape of MET alterations in non-small cell lung cancer in Southeastern China: a real-world study.

Journal: BMC cancer

Published: March 31, 2026

A weakly supervised deep learning-based recurrence prediction and risk stratification of lung adenocarcinoma from pathology whole-slide images.

A weakly supervised deep learning-based recurrence prediction and risk stratification of lung adenocarcinoma from pathology whole-slide images.

Journal: BMC cancer

Published: March 28, 2026

Immunotherapy and the Sequence Relative to Survival Outcomes in SCLC: Analysis of the National Cancer Database.

Immunotherapy and the Sequence Relative to Survival Outcomes in SCLC: Analysis of the National Cancer Database.

Journal: Cancers

Published: December 12, 2025

Identifying prioritization of potential targets for idiopathic pulmonary fibrosis: Proteome-wide Mendelian randomization and colocalization analyses.

Identifying prioritization of potential targets for idiopathic pulmonary fibrosis: Proteome-wide Mendelian randomization and colocalization analyses.

Journal: Clinics (Sao Paulo, Brazil)

Published: September 09, 2025

Engineering Stimuli-Responsive Materials for Precision Medicine.

Engineering Stimuli-Responsive Materials for Precision Medicine.

Journal: Small (Weinheim an der Bergstrasse, Germany)

Published: July 28, 2024

Exploring the causal effect between lipid-modifying drugs and idiopathic pulmonary fibrosis: a drug-target Mendelian randomization study.

Exploring the causal effect between lipid-modifying drugs and idiopathic pulmonary fibrosis: a drug-target Mendelian randomization study.

Journal: Lipids in health and disease

Published: May 08, 2024

Fibroblast Growth Factor 21 Relieves Lipopolysaccharide-Induced Acute Lung Injury by Suppressing JAK2/STAT3 Signaling Pathway.

Fibroblast Growth Factor 21 Relieves Lipopolysaccharide-Induced Acute Lung Injury by Suppressing JAK2/STAT3 Signaling Pathway.

Journal: Inflammation

Published: February 19, 2023

FGF21 alleviates pulmonary hypertension by inhibiting mTORC1/EIF4EBP1 pathway via H19.

FGF21 alleviates pulmonary hypertension by inhibiting mTORC1/EIF4EBP1 pathway via H19.

Journal: Journal of cellular and molecular medicine

Published: December 31, 2021

Maresin 1 intervention reverses experimental pulmonary arterial hypertension in mice.

Maresin 1 intervention reverses experimental pulmonary arterial hypertension in mice.

Journal: British journal of pharmacology

Published: October 20, 2021

FGF21 attenuates pulmonary arterial hypertension via downregulation of miR-130, which targets PPARγ.

FGF21 attenuates pulmonary arterial hypertension via downregulation of miR-130, which targets PPARγ.

Journal: Journal of cellular and molecular medicine

Published: July 24, 2021

Integrated bioinformatic analysis reveals the underlying molecular mechanism of and potential drugs for pulmonary arterial hypertension.

Integrated bioinformatic analysis reveals the underlying molecular mechanism of and potential drugs for pulmonary arterial hypertension.

Journal: Aging

Published: November 18, 2020

CCR7 and its related molecules may be potential biomarkers of pulmonary arterial hypertension.

CCR7 and its related molecules may be potential biomarkers of pulmonary arterial hypertension.

Journal: FEBS open bio

Published: October 26, 2020

Showing 1-12 of 16

Last Updated: 09/26/2026